216983-39-0

Basic information

• Product Name: 1-[(4-fluorophenyl)sulfonyl]piperidin-4-one
• Synonyms: 1-[(4-fluorophenyl)sulfonyl]piperidin-4-one;1-(4-fluorophenyl)sulfonyl-4-piperidinone;1-(4-fluorophenyl)sulfonyl-4-piperidone
• CAS NO: 216983-39-0
• Molecular Formula: C₁₁H₁₂FNO₃S
• Molecular Weight: 257.2812832
• Mol File: 216983-39-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-[(4-fluorophenyl)sulfonyl]piperidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(4-fluorophenyl)sulfonyl]piperidin-4-one(216983-39-0)
• EPA Substance Registry System: 1-[(4-fluorophenyl)sulfonyl]piperidin-4-one(216983-39-0)

Safety Data

• Hazardous Substances Data: 216983-39-0(Hazardous Substances Data)

Upstream product

• 368-88-7 4-fluorobenzenesulfonic acid 
• 41661-47-6 piperidin-4-one 
• 349-88-2 4-Fluorobenzenesulfonyl chloride 
• 40064-34-4 4-piperidone monohydrochloride monohydrate 

Downstream Products

• 216983-42-5 3-Bromo-1-(4-fluoro-benzenesulfonyl)-piperidin-4-one 
• 1224590-92-4 C₁₃H₁₇FN₂O₃S 
• 250291-66-8 6-(4-Fluoro-benzenesulfonyl)-octahydro-pyrido[3,4-b][1,4]thiazine-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide 
• 250291-64-6 6-(4-Fluoro-benzenesulfonyl)-octahydro-pyrido[3,4-b][1,4]thiazine-1-carboxylic acid (3,4-dichloro-phenyl)-amide 
• 250291-63-5 6-(4-Fluoro-benzenesulfonyl)-octahydro-pyrido[3,4-b][1,4]thiazine-1-carboxylic acid (4-methoxy-phenyl)-amide 
• 250291-65-7 6-(4-Fluoro-benzenesulfonyl)-octahydro-pyrido[3,4-b][1,4]thiazine-1-carboxylic acid phenylamide 
• 250291-61-3 {2-[1-(4-Fluoro-benzenesulfonyl)-4-oxo-piperidin-3-ylsulfanyl]-ethyl}-carbamic acid tert-butyl ester 
• 250291-62-4 6-(4-Fluoro-benzenesulfonyl)-octahydro-pyrido[3,4-b][1,4]thiazine 

Relevant articles and documents

COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF

The compounds of Formula (I) which can be used as CRTH2 receptor antagonists are provided. The compounds of Formula (I) can be used in the treatment and prevention of asthma, allergic rhinitis and atopic dermatitis, as well as other diseases mediated by prostaglandin D2 (PGD2) at the CRTH2 receptor.

NOVEL ANALGESIC THAT BINDS FILAMIN A

A compound, composition and method are disclosed that can provide analgesia. A contemplated compound has a structure that corresponds to Formula I, wherein R1 and R2 are substituents, and n, W, X and Y are defined within.

DISPIRO TETRAOXANE COMPOUNDS

A compound having the formula (I) wherein ring A represents a substituted or unsubstituted monocyclic or multicyclic ring; m=any positive integer; n=0-5; X=CH and Y=-C(O)NR1R2, -NR1R2 or -S(O)2R4, where R1, R2 and R4 are each individually selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted amine, substituted or unsubstituted carbocyclic ring, substituted or unsubstituted heterocyclic ring, or any combination thereof, or R1 and R2 are linked so as to form part of a substituted or unsubstituted heterocyclic ring, or X=N and Y=-S(O)2R3 or -C(O)R3, where R3 is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted amine, substituted or unsubstituted carbocyclic ring, substituted or unsubstituted heterocyclic ring or any combination thereof.

5-HT7 receptor antagonists

The present invention relates to compounds having pharmacological activity toward the 5-HT7receptor. Pharmaceutical compositions and methods for their use in the treatment of CNS disorders are described.